



## Hitomi Hosoya, MD, PhD

Instructor, Medicine - Blood & Marrow Transplantation

### CLINICAL OFFICE (PRIMARY)

- **Hematology**

269 Campus Dr Rm 1155

CCSR Bldg MC 5156

Stanford, CA 94305

**Tel** (650) 726-1484      **Fax** (650) 724-5203

### Bio

---

#### BIO

Dr. Hosoya is fellowship-trained in blood and marrow transplantation, cellular therapy and hematology with the Stanford Medicine Cancer Center and an instructor at Stanford University in the Department of Medicine, Division of Blood & Marrow Transplantation and Cellular Therapy.

Her areas of expertise include transplantation, immunotherapies, and cellular therapies for patients with multiple myeloma and other plasma cell disorders. She diagnoses and treats a range of blood disorders from anemia and hemophilia to cancerous conditions like leukemia and multiple myeloma. For each patient, she prepares a personalized, comprehensive, and compassionate care plan.

Dr. Hosoya's research is focused on improving cancer diagnostics and therapeutic decision-making in multiple myeloma. She is specifically interested in the genomics of multiple myeloma and its evolution over the course of the disease. Dr. Hosoya is studying the role of circulating tumor DNA (ctDNA) in patients with multiple myeloma and developing tools to detect and quantify tumors and their response to chemotherapy and immunotherapy, with a goal of informing personalized therapies.

Dr. Hosoya demonstrated ctDNA is useful in detecting and monitoring tumor, and its prognostic value for patients undergoing CAR T-cell therapy in multiple myeloma. Her ongoing research is focused on applying cell-free DNA sequencing towards sensitive detection of copy number alterations, gene expression inferences, and understanding mechanisms of disease response and resistance in diverse therapies in multiple myeloma.

Dr. Hosoya is a member of the Society for Immunotherapy of Cancer, American Society of Clinical Oncology, American Society of Hematology, and the Japan Team Oncology Program.

#### CLINICAL FOCUS

- Myeloma/Multiple Myeloma
- Amyloidosis
- POEMS Syndrome
- Waldenstrom's Macroglobulinemia

- CAR-T cell Therapy
- Hematopoietic Stem Cell Transplantation
- Hematology

## ACADEMIC APPOINTMENTS

- Instructor, Medicine - Blood & Marrow Transplantation

## PROFESSIONAL EDUCATION

- Medical Education: The University of Tokyo (2009) Japan
- Board Certification: Hematology, American Board of Internal Medicine (2022)
- Fellowship: Stanford University Bone Marrow Transplant Fellowship (2023) CA
- Fellowship: Stanford University Hematology and Oncology Fellowship (2022) CA
- Board Certification: Internal Medicine, American Board of Internal Medicine (2019)
- Residency: University of Pennsylvania Internal Medicine Residency (2019) PA

## Publications

---

### PUBLICATIONS

- **Bendamustine vs. fludarabine/cyclophosphamide lymphodepletion prior to BCMA CAR-T cell therapy in multiple myeloma.** *Blood cancer journal*  
Sidana, S., Hosoya, H., Jensen, A., Liu, L., Goyal, A., Hovanky, V., Sahaf, B., Bharadwaj, S., Latchford, T., Arai, S., Leahy, S., Mei, M., Budde, et al  
2023; 13 (1): 158
- **Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed/refractory multiple myeloma with renal impairment.** *Haematologica*  
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C., Khouri, J., Dima, D., Atrash, S., Voorhees, P., Simmons, G., Sborov, D. W., Kalariya, N., Hovanky, et al  
2023
- **Embracing Myeloma Chimeric Antigen Receptor-T: From Scientific Design to Clinical Impact.** *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*  
Hosoya, H., Rodriguez-Otero, P., Sidana, S., Borrello, I. M.  
2023; 43: e389860
- **Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas.** *Cancer cell*  
Sworder, B. J., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N., Garofalo, A., Macaulay, C. W., Shahrokh Esfahani, M., Olsen, M. N., Hamilton, J., Hosoya, H., Hamilton, M., Spiegel, et al  
2022
- **Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas**  
Sworder, B., Kurtz, D. M., Alig, S. K., Frank, M. J., Shukla, N. D., Garofalo, A., Macaulay, C., Esfahani, M., Olsen, M., Hamilton, J., Hosoya, H., Hamilton, M. P., Spiegel, et al  
AMER SOC HEMATOLOGY.2022: 1301-1303
- **Accurate Detection of Clinically Actionable Copy Number Variants in Diverse Hematological Neoplasms By Routine Targeted Sequencing: A Comparative Performance Study**  
Mosquera, A., Hosoya, H., Jin, M. C., Esfahani, M., Schroers-Martin, J., Sworder, B., Liu, C., Spiteri, E., Natkunam, Y., Zehnder, J. L., Stehr, H., Kurtz, D. M., Alizadeh, et al  
AMER SOC HEMATOLOGY.2022: 10712-10713
- **Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience**  
Sidana, S., Peres, L. C., Hashmi, H., Hosoya, H., Ferreri, C. J., Atrash, S., Khouri, J., Voorhees, P. M., Dima, D., Simmons, G., Kalariya, N., Hovanky, V., Bharadwaj, et al  
AMER SOC HEMATOLOGY.2022: 10377-10379
- **Disease Characterization and Response Prediction in Myeloma Patients Undergoing Conventional and Cellular Therapies from Circulating Tumor DNA**

---

Hosoya, H., Carleton, M., Tanaka, K. L., Sworder, B., Hovanky, V., Duran, G. E., Zhang, T. Y., Khodadoust, M. S., Miklos, D. B., Arai, S., Iberri, D., Liedtke, M., Sidana, et al

AMER SOC HEMATOLOGY.2022: 1546-1548

- **Early cytopenias and infections after standard of care idecabtagene vicleucel#in relapsed or refractory multiple myeloma.***Blood advances*  
Logue, J. M., Peres, L. C., Hashmi, H., Colin-Leitzinger, C., Shrewsbury, A. M., Hosoya, H., Gonzalez, R., Copponex, C., Kottra, K. H., Hovanky, V., Sahaf, B., Patil, S., Lazaryan, et al  
2022
- **Mgta-145+Plerixafor Provides GCSF-free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study**  
Sidana, S., Bankova, A. K., Hosoya, H., Kumar, S., Tamareisis, J., Le, A., Muffly, L., Johnston, L. J., Arai, S., Lowsky, R., Meyer, E. H., Rezvani, A. R., Weng, et al  
AMER SOC HEMATOLOGY.2021
- **Phase 2 study of MGTA-145+plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.**  
Sidana, S., Bankova, A., Hosoya, H., Muffly, L. S., Kumar, S., Johnston, L. J., Lowsky, R., Meyer, E., Rezvani, A., Weng, W., Arai, S., Frank, M., Shiraz, et al  
LIPPINCOTT WILLIAMS & WILKINS.2021
- **Antibody-Based Treatment Approaches in Multiple Myeloma.** *Current hematologic malignancy reports*  
Hosoya, H., Sidana, S.  
2021